C. Morrow

发表

[18F]-FLT Positron Emission Tomography Can Be Used to Image the Response of Sensitive Tumors to PI3-Kinase Inhibition with the Novel Agent GDC-0941

K. Williams, C. Dive, Gavin Brown, 2013, Molecular Cancer Therapeutics.

Activating ESR1 Mutations Differentially Affect the Efficacy of ER Antagonists.

S. Chandarlapaty, J. Baselga, J. Katzenellenbogen, 2017, Cancer discovery.

Src family kinase inhibitor Saracatinib (AZD0530) impairs oxaliplatin uptake in colorectal cancer cells and blocks organic cation transporters.

Mohammad A. Ghattas, H. Bönisch, C. Dive, 2010, Cancer research.

Serial monitoring of genomic alterations in circulating tumor cells of ER‐positive/HER2‐negative advanced breast cancer: feasibility of precision oncology biomarker detection

Manish R. Patel, S. Tomlins, J. Barrett, 2021, Molecular oncology.

Tumourigenic non-small-cell lung cancer mesenchymal circulating tumour cells: a clinical case study

C. Dive, F. Blackhall, D. Nonaka, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Molecular analysis of circulating tumor cells identifies distinct copy-number profiles in patients with chemosensitive and chemorefractory small-cell lung cancer

Crispin J. Miller, Christopher Smowton, Yaoyong Li, 2016, Nature Medicine.

BMX acts downstream of PI3K to promote colorectal cancer cell survival and pathway inhibition sensitizes to the BH3 mimetic ABT-737.

L. Stephens, C. Dive, C. Morrow, 2014, Neoplasia.

Genome engineering for estrogen receptor mutations reveals differential responses to anti-estrogens and new prognostic gene signatures for breast cancer

Simak Ali, Chun-Fui Lai, A. Harrod, 2022, Oncogene.

The Novel Bcl-2 Inhibitor ABT-737 Is More Effective in Hypoxia and Is Able to Reverse Hypoxia-Induced Drug Resistance in Neuroblastoma Cells

C. Dive, M. Brandenburg, C. Morrow, 2011, Molecular Cancer Therapeutics.

Tumorigenicity and genetic profiling of circulating tumor cells in small-cell lung cancer

Mahmood Ayub, Dominic G Rothwell, Caroline Dive, 2014, Nature Medicine.

Comparison of phosphatidylinositol‐3‐kinase signalling within a panel of human colorectal cancer cell lines with mutant or wild‐type PIK3CA

C. Dive, A. Gray, C. Morrow, 2005, FEBS letters.

Identification and Targeting of Long-Term Tumor-Propagating Cells in Small Cell Lung Cancer.

J. Sage, N. Jahchan, P. Mazur, 2016, Cell reports.

Identification and Targetin g of Long-Term Tumor-Propagating Cells in Small Cell Lung Cancer Graphical

J. Sage, N. Jahchan, P. Mazur, 2016 .

Activity of the Monocarboxylate Transporter 1 Inhibitor AZD3965 in Small Cell Lung Cancer

Paul D. Smith, C. Dive, F. Blackhall, 2013, Clinical Cancer Research.

Blocking Phosphoinositide 3-Kinase Activity in Colorectal Cancer Cells Reduces Proliferation but Does Not Increase Apoptosis Alone or in Combination with Cytotoxic Drugs

C. Dive, M. Welham, C. Morrow, 2009, Molecular Cancer Research.

Cancer Therapy : Preclinical Activity of the Monocarboxylate Transporter 1 Inhibitor AZD 3965 in Small Cell Lung Cancer

Paul D. Smith, C. Dive, F. Blackhall, 2014 .

The Combination of the PARP Inhibitor Olaparib and the WEE1 Inhibitor AZD1775 as a New Therapeutic Option for Small Cell Lung Cancer

Crispin J. Miller, S. Gulati, M. O’Connor, 2018, Clinical Cancer Research.

Cancer Therapy: Preclinical Activity of the Monocarboxylate Transporter 1 Inhibitor AZD3965 in Small Cell Lung Cancer

Paul D. Smith, A. White, C. Dive, 2014 .

Bub1 and aurora B cooperate to maintain BubR1-mediated inhibition of APC/CCdc20

Stephen S. Taylor, V. L. Johnson, Maria I F Scott, 2005, Journal of Cell Science.

Hypoxic human cancer cells are sensitized to BH-3 mimetic–induced apoptosis via downregulation of the Bcl-2 protein Mcl-1.

C. Dive, D. Micha, F. Blackhall, 2011, The Journal of clinical investigation.

Abstract 5674: Discovery of AZD9833, an oral small molecule selective degrader of the estrogen receptor (SERD)

James S. Scott, T. Moss, C. Morrow, 2020 .

Kinetochore localisation and phosphorylation of the mitotic checkpoint components Bub1 and BubR1 are differentially regulated by spindle events in human cells.

Stephen S. Taylor, S. Taylor, S. Elderkin, 2001, Journal of cell science.

Inhibition of PI3K/BMX Cell Survival Pathway Sensitizes to BH3 Mimetics in SCLC

C. Dive, F. Blackhall, C. Morrow, 2016, Molecular Cancer Therapeutics.

Abstract GS3-02: GS3-02 Camizestrant, a next generation oral SERD vs fulvestrant in post-menopausal women with advanced ER-positive HER2-negative breast cancer: Results of the randomized, multi-dose Phase 2 SERENA-2 trial

P. Neven, Y. Hotko, H. Denys, 2023, Cancer Research.

Serena-1: Updated analyses from a phase 1 study (parts C/D) of the next-generation oral SERD camizestrant (AZD9833) in combination with palbociclib, in women with ER-positive, HER2-negative advanced breast cancer.

P. Kabos, C. Twelves, N. Turner, 2022, Journal of Clinical Oncology.

Abstract PS11-05: Updated data from SERENA-1: A Phase 1 dose escalation and expansion study of the next generation oral SERD AZD9833 as a monotherapy and in combination with palbociclib, in women with ER-positive, HER2-negative advanced breast cancer

A. Cohen, U. Banerji, P. Kabos, 2021 .

Somatically mutated ABL1 is an actionable and essential NSCLC survival gene

Caroline Dive, J. Brognard, P. Torres-Ayuso, 2016, EMBO molecular medicine.

Development of a circulating miRNA assay to monitor tumor burden: From mouse to man

C. Dive, F. Blackhall, L. Carter, 2015, Molecular oncology.

Discovery of AZD9833, a potent and orally bioavailable selective estrogen receptor degrader and antagonist.

O. Delpuech, J. Breed, J. Nissink, 2020, Journal of medicinal chemistry.

Tricyclic Indazoles-A Novel Class of Selective Estrogen Receptor Degrader Antagonists.

Paul R. J. Davey, James S. Scott, A. Bailey, 2019, Journal of medicinal chemistry.

Building Bridges in a Series of Estrogen Receptor Degraders: An Application of Metathesis in Medicinal Chemistry.

J. Breed, J. Nissink, Paul R. J. Davey, 2019, ACS medicinal chemistry letters.

Discovery of a Potent and Orally Bioavailable Zwitterionic Series of Selective Estrogen Receptor Degrader-Antagonists.

J. Breed, J. Nissink, Paul R. J. Davey, 2023, Journal of medicinal chemistry.

Molecular analysis of circulating tumor cells identifies distinct copy-number profiles in patients with chemosensitive and chemorefractory small-cell lung cancer

Crispin J. Miller, Christopher Smowton, Yaoyong Li, 2016, Nature Medicine.

Identification and Targeting of Long-Term Tumor-Propagating Cells in Small Cell Lung Cancer.

J. Sage, N. Jahchan, Dian Yang, 2016, Cell reports.